Effects of Rituximab on COVID-19 Outcomes in Immunocompromised Koreans
Overview
This nationwide Korean study evaluated rituximab (RTX) use in immunocompromised adults and its association with SARS-CoV-2 infection and COVID-19 severity. RTX use in vaccinated individuals was linked to increased hospitalization and ICU admission, while no significant associations were found in unvaccinated patients.
Background
Anti-CD20 therapies like rituximab are used in various immunosuppressive conditions but have been associated with severe COVID-19 outcomes, including pneumonia and prolonged viral shedding. Prior studies were limited by small sample sizes and specific populations, leaving the broader impact unclear, especially in the context of widespread COVID-19 vaccination. This study leveraged a comprehensive nationwide Korean database integrating COVID-19 registry and health insurance claims to assess the risks associated with RTX use during the pandemic.
Data Highlights
Group
Outcome
Adjusted Odds Ratio (aOR)
95% Confidence Interval
P-value
Vaccinated RTX users
SARS-CoV-2 infection
1.75
0.82–3.72
0.149
Vaccinated RTX users
Hospitalization for COVID-19
2.64
1.14–6.10
0.024
Vaccinated RTX users
ICU admission
10.89
1.44–82.46
0.021
Unvaccinated RTX users
Severe COVID-19 outcomes
Not significant
Not significant
Not significant
Key Findings
Among 1,548,038 patients requiring anti-CD20 therapy, 1,457,171 were vaccinated and 90,867 unvaccinated.
In vaccinated patients, RTX use was not significantly associated with increased SARS-CoV-2 infection risk (aOR 1.75; P=0.149).
RTX use in vaccinated individuals was significantly associated with higher risk of COVID-19 hospitalization (aOR 2.64; P=0.024).
RTX use in vaccinated patients was linked to markedly increased ICU admission risk (aOR 10.89; P=0.021).
No statistically significant associations between RTX use and severe COVID-19 outcomes were observed in unvaccinated patients.
Clinical Implications
Clinicians should recognize that rituximab use in vaccinated immunocompromised patients may increase the risk of severe COVID-19 outcomes, including hospitalization and ICU admission. Despite vaccination, careful risk-benefit assessment is warranted when initiating anti-CD20 therapy during the pandemic. Enhanced monitoring and preventive strategies may be necessary for this vulnerable population.
Conclusion
This large nationwide study demonstrates that rituximab use is associated with increased severity of COVID-19 outcomes in vaccinated immunocompromised individuals. These findings underscore the need for cautious clinical decision-making regarding anti-CD20 therapy amid ongoing SARS-CoV-2 circulation.
References
Korea Disease Control and Prevention Agency & National Health Insurance Service 2022 -- Effects of Rituximab on COVID-19 Outcomes in Immunocompromised Individuals
